Scenarios of MTC in people treated with liraglutide, Yet another GLP-1 receptor agonist, have already been described from the postmarketing period of time; the information in these studies are insufficient to determine or exclude a causal marriage concerning MTC and GLP-1 receptor agonist use in people. to scale back the risk of kidney disease w